Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Xeris Biopharma Holdings, Inc.’s reported figures.
Plus components not separately reported this period.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
FAQ
- What is Xeris Biopharma Holdings, Inc.'s EBIT?
- Xeris Biopharma Holdings, Inc. (XERS) reported EBIT of $5.17M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s EBIT changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s EBIT increased by 15.4% year-over-year, from $4.48M to $5.17M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s EBIT has grown at a -31.8% compound annual growth rate (CAGR), from -$115.16M to $24.9M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Xeris Biopharma Holdings, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude